Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

FDA approvable letter issued for Indevus' drug candidate Valstar

Aug. 22, 2007

Cell Therapeutics to acquire Zevalin from Biogen Idec for U.S. sales and marketing

Aug. 22, 2007

New anticancer agents claimed by several research groups

Aug. 22, 2007

EMEA reviews new indication for Bioenvision's Evoltra

Aug. 21, 2007

FDA grants fast track designation to Adventrx's CoFactor

Aug. 21, 2007

Myriad begins third phase II trial of Azixa for lung cancer spread to the brain

Aug. 21, 2007

Recent patents cover HDAC inhibitors primarily for cancer

Aug. 21, 2007

The MMRC and Proteolix start carfilzomib phase II clinical trial in multiple myeloma

Aug. 20, 2007

EMEA recommends orphan drug status for Progen's PI-88 as it enters phase III trial

Aug. 20, 2007

Vion enrolls 85 elderly patients in pivotal phase II trial of Cloretazine for AML

Aug. 20, 2007

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...